Literature DB >> 34840905

Multiple Streptococcal Brain Abscesses in a Patient Taking Secukinumab.

Anjali Bhatla1, Melissa Asmar1, Defne A Amado1.   

Abstract

Entities:  

Year:  2021        PMID： 34840905      PMCID： PMC8610518          DOI： 10.1212/CPJ.0000000000000964

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

1.  Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection.

Authors:  Beinan Wang; Thamotharampillai Dileepan; Sarah Briscoe; Kendra A Hyland; Johnthomas Kang; Alexander Khoruts; P Patrick Cleary
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

Authors:  Peter C M van de Kerkhof; Christopher E M Griffiths; Kristian Reich; Craig L Leonardi; Andrew Blauvelt; Tsen-Fang Tsai; Yankun Gong; Jiaqing Huang; Charis Papavassilis; Todd Fox
Journal:  J Am Acad Dermatol       Date:  2016-05-12       Impact factor: 11.527

3.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

4.  Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity.

Authors:  Ozer Arican; Murat Aral; Sezai Sasmaz; Pinar Ciragil
Journal:  Mediators Inflamm       Date:  2005-10-24       Impact factor: 4.711

5.  Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Authors:  Stefan Schreiber; Jean-Frederic Colombel; Brian G Feagan; Kristian Reich; Atul A Deodhar; Iain B McInnes; Brian Porter; Ayan Das Gupta; Luminita Pricop; Todd Fox
Journal:  Ann Rheum Dis       Date:  2019-01-23       Impact factor: 19.103

6.  Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis.

Authors:  Li Zhang; Hua Yang; Qihong Chen; Jing Zhao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.